The Feasibility of C-PIB-PET/CT for Amyloid Plaque Burden: Validation of the Effectiveness of CT-based Partial Volume Correction

Overview

Journal Brain Behav

Specialty Psychology

Date 2016 Oct 27

PMID 27781145

Citations 4

Authors

Kei Sasaki

Norihide Maikusa

Etsuko Imabayashi

Tetsuya Yuasa

Hiroshi Matsuda

Affiliations

Soon will be listed here.

Abstract

Introduction: Amyloid positron-emission tomography (PET) imaging with C-Pittsburgh compound B (PiB) is an effective tool for assessing brain amyloid deposits. PET imaging, however, can suffer from the partial volume effect (PVE). PVE has been corrected using MRI (magnetic resonance imaging) image data. However, correction of the PVE of PET using MRI usually requires two separate procedures, imposing a burden on patients and leading to low throughput and inefficient diagnoses. The advent of PET/computed tomography (PET/CT) may potentially overcome these problems and offer higher throughput and reliable quantification of amyloid plaques and assessment of Alzheimer disease (AD).

Methods: We investigated the feasibility of correcting PVE in amyloid PET using CT, obtained by PET/CT, instead of MRI. We demonstrated the efficacy of partial volume correction (PVC) based on CT by comparing the results of CT-based PVC and those of MRI-based PVC using images acquired from AD patients and controls.

Results: Both methods were able to perform PVC. Slight but significant differences between standard uptake volume ratio (SUVR) values were noted between the two modalities; these were attenuated by constant multiplication.

Conclusion: CT will potentially replace MRI for PVC, allowing the use of a single PET/CT scanner for amyloid plaque quantitation.

Citing Articles

Neuroimaging of Alzheimer's disease: focus on amyloid and tau PET.

Matsuda H, Shigemoto Y, Sato N Jpn J Radiol. 2019; 37(11):735-749.

PMID: 31493197 DOI: 10.1007/s11604-019-00867-7.

Amyloid burden identifies neuropsychological phenotypes at increased risk of progression to Alzheimer's disease in mild cognitive impairment patients.

Ciarmiello A, Tartaglione A, Giovannini E, Riondato M, Giovacchini G, Ferrando O Eur J Nucl Med Mol Imaging. 2018; 46(2):288-296.

PMID: 30244387 PMC: 6333718. DOI: 10.1007/s00259-018-4149-2.

The feasibility of C-PIB-PET/CT for amyloid plaque burden: validation of the effectiveness of CT-based partial volume correction.

Sasaki K, Maikusa N, Imabayashi E, Yuasa T, Matsuda H Brain Behav. 2016; 6(10):e00532.

PMID: 27781145 PMC: 5064343. DOI: 10.1002/brb3.532.

Computed-tomography-guided anatomic standardization for quantitative assessment of dopamine transporter SPECT.

Yokoyama K, Imabayashi E, Sumida K, Sone D, Kimura Y, Sato N Eur J Nucl Med Mol Imaging. 2016; 44(3):366-372.

PMID: 27544223 DOI: 10.1007/s00259-016-3496-0.

References

Braak H, Braak E . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-59. DOI: 10.1007/BF00308809. View

Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N . Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002; 15(1):273-89. DOI: 10.1006/nimg.2001.0978. View

Drzezga A, Grimmer T, Henriksen G, Stangier I, Perneczky R, Diehl-Schmid J . Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage. 2007; 39(2):619-33. DOI: 10.1016/j.neuroimage.2007.09.020. View

Schoder H, Erdi Y, Larson S, Yeung H . PET/CT: a new imaging technology in nuclear medicine. Eur J Nucl Med Mol Imaging. 2003; 30(10):1419-37. DOI: 10.1007/s00259-003-1299-6. View

Brockschnieder D, Schmitt-Willich H, Heinrich T, Varrone A, Gulyas B, Toth M . Preclinical characterization of a novel class of 18F-labeled PET tracers for amyloid-β. J Nucl Med. 2012; 53(11):1794-801. DOI: 10.2967/jnumed.112.104810. View

Zhang Q, Powers E, Nieva J, Huff M, Dendle M, Bieschke J . Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc Natl Acad Sci U S A. 2004; 101(14):4752-7. PMC: 387320. DOI: 10.1073/pnas.0400924101. View

Sasaki K, Maikusa N, Imabayashi E, Yuasa T, Matsuda H . The feasibility of C-PIB-PET/CT for amyloid plaque burden: validation of the effectiveness of CT-based partial volume correction. Brain Behav. 2016; 6(10):e00532. PMC: 5064343. DOI: 10.1002/brb3.532. View

Price J, Klunk W, Lopresti B, Lu X, Hoge J, Ziolko S . Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005; 25(11):1528-47. DOI: 10.1038/sj.jcbfm.9600146. View

Hosokawa C, Ishii K, Kimura Y, Hyodo T, Hosono M, Sakaguchi K . Performance of 11C-Pittsburgh Compound B PET Binding Potential Images in the Detection of Amyloid Deposits on Equivocal Static Images. J Nucl Med. 2015; 56(12):1910-5. DOI: 10.2967/jnumed.115.156414. View

10.

Rabinovici G, Jagust W, Furst A, Ogar J, Racine C, Mormino E . Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol. 2008; 64(4):388-401. PMC: 2648510. DOI: 10.1002/ana.21451. View

11.

Wolk D, Price J, Saxton J, Snitz B, James J, Lopez O . Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009; 65(5):557-68. PMC: 2828870. DOI: 10.1002/ana.21598. View

12.

Payoux P, Delrieu J, Gallini A, Adel D, Salabert A, Hitzel A . Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings. Eur J Nucl Med Mol Imaging. 2015; 42(9):1459-68. DOI: 10.1007/s00259-015-3067-9. View

13.

Kato H, Shimosegawa E, Oku N, Kitagawa K, Kishima H, Saitoh Y . MRI-based correction for partial-volume effect improves detectability of intractable epileptogenic foci on 123I-iomazenil brain SPECT images. J Nucl Med. 2008; 49(3):383-9. DOI: 10.2967/jnumed.107.046136. View

14.

Ikonomovic M, Klunk W, Abrahamson E, Mathis C, Price J, Tsopelas N . Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008; 131(Pt 6):1630-45. PMC: 2408940. DOI: 10.1093/brain/awn016. View

15.

Sled J, Zijdenbos A, Evans A . A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging. 1998; 17(1):87-97. DOI: 10.1109/42.668698. View

16.

Quarantelli M, Berkouk K, Prinster A, Landeau B, Svarer C, Balkay L . Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction. J Nucl Med. 2004; 45(2):192-201. View

17.

Giovacchini G, Lerner A, Toczek M, Fraser C, Ma K, DeMar J . Brain incorporation of 11C-arachidonic acid, blood volume, and blood flow in healthy aging: a study with partial-volume correction. J Nucl Med. 2004; 45(9):1471-9. View

18.

Jack Jr C, Bernstein M, Fox N, Thompson P, Alexander G, Harvey D . The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008; 27(4):685-91. PMC: 2544629. DOI: 10.1002/jmri.21049. View

19.

Maikusa N, Yamashita F, Tanaka K, Abe O, Kawaguchi A, Kabasawa H . Improved volumetric measurement of brain structure with a distortion correction procedure using an ADNI phantom. Med Phys. 2013; 40(6):062303. DOI: 10.1118/1.4801913. View

20.

Forster S, Yousefi B, Wester H, Klupp E, Rominger A, Forstl H . Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2012; 39(12):1927-36. DOI: 10.1007/s00259-012-2230-9. View